Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MGTA - Dianthus Therapeutics Inc


Close
0.71
0.710   100.000%

Share volume: 0
Last Updated: Mon 11 Sep 2023 09:11:22 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%

N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
5%
Profitability 0%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
4.00%
6 Months
-5.64%
1 Year
-5.64%
2 Year
-5.64%
Key data
Stock price
$0.71
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$26.76 - $30.37
52 WEEK CHANGE
-$5.64
MARKET CAP 
45.141 M
YIELD 
N/A
SHARES OUTSTANDING 
60.665 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/02/2023
BETA 
0.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Jason Gardner
Region: US
Website: https://www.magentatx.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

Recent news